SmallCapReview - Small Cap Stocks on the Move - BTRX, MGI, EMIS, EMAG
Winston-Salem 6/23/2008 03:35 PM GMT (TransWorldNews)
To register for the Free SmallCapReview Newsletter and automatically be entered to win a Blackberry Pearl visit http://www.smallcapreview.com/subscribe.htm
Barrier Therapeutics (Nasdaq BTRX) Tradiong at $4.02. Up $2.26. Today announced that it has signed a definitive merger agreement with Stiefel Laboratories, the world's largest independent pharmaceutical company specializing in dermatology. Under the agreement, Stiefel Laboratories will purchase all of the outstanding shares of Barrier Therapeutics at a price of $4.15 per share in cash, representing a 73% premium to Barrier Therapeutics' average closing price for the past 30 days. The transaction, valued at approximately $148 million, is subject to the valid tender of a majority of Barrier Therapeutics' fully diluted common stock, regulatory approvals and other customary conditions, but is not subject to any financing conditions. The parties expect the transaction to close by the end of the third quarter of 2008.
What They Do: Barrier Therapeutics is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(r) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(r) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections.
How They Trade: BTRX has a 52 week high of $7.60 and a 52 week low of $1.63. Volume averages approximately 172K shares a day.
MoneyGram International (NYSE: MGI) Trading at $1.20, Up $0.17. Today announced today that on June 20, 2008, its common stock began actively trading on NYSE Arca, a national securities exchange owned by NYSE Euronext. The Company’s ticker symbol (MGI) has not changed and the Company remains listed on the NYSE.
The Company’s common stock will resume trading on the NYSE floor trading system once it trades at or above $1.10 per share for a full trading day. The Company continues to be subject to the rules and regulations of the NYSE and remains in compliance with the continued listing standards of the NYSE.
What They Do: MoneyGram International, Inc. is a leading global payment services company. The company's major products and services include global money transfers, money orders and payment processing solutions for financial institutions and retail customers. MoneyGram is a New York Stock Exchange listed company with approximately 152,000 global money transfer agent locations in 180 countries and territories.
How They Trade: Volume averages approximately 1.5M shares a day.
Emisphere Technologies (Nasdaq: EMIS) Trading at $2.32, Up $0.34. Today announced they and Novo Nordisk A/S (NYSE: NVO) have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's proprietary GLP-1 receptor agonists, which have the potential of treating Type 2 diabetes, using Emisphere's eligen® technology. The agreement includes at least $87 million in product development and sales milestone payments to Emisphere, of which $10 million will be the minimum first year payment, as well as royalties on sales. The agreement also provides Novo Nordisk with the option to develop oral formulations of Novo Nordisk compounds other than GLP-1 receptor agonists using Emisphere's proprietary carrier technology. Further financial details of the agreement were not made public.
What They Do: Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen® Technology. Some of these molecules or compounds can only be given by injection; when combined with our technology; convenient oral versions may be safe, effective and provide significant advantages. The benefits of other compounds are limited due to poor bioavailability, slow on-set of action or variable absorption.
How They Trade: EMIS has a 52 week high of $5.17 and a 52 week low of $1.28. Volume averages approximately 66K shares a day.
Emageon Inc. (Nasdaq: EMAG) Trading at $2.69, Up $0.34. Today announced it has reached an agreement with Oliver Press Partners, LLC under which three new directors will join the Emageon Board of Directors. Augustus Oliver, a principal of Oliver Press Partners and Benner Ulrich, Director of Research at Oliver Press Partners, will be elected to the Board today for a term expiring at the 2010 Annual Meeting, and a third new independent director selected by Oliver Press will also be added for a term expiring at the 2011 Annual Meeting. Additionally, Benner Ulrich and the to-be-named new director, upon his election, will be appointed to the company's Strategic Alternatives Committee, which has a broad mandate to pursue all strategic alternatives for Emageon, including a sale of the company.
What They Do: Emageon provides information technology systems for hospitals, healthcare networks and imaging facilities. Its enterprise family of solutions includes RadSuite(TM), HeartSuite(TM) and other specialty suites. All Emageon solutions are built on a unified Enterprise Content Management system offering advanced visualization and infrastructure tools for the clinical analysis and management of digital medical images, reports and associated clinical content. Emageon's standards-based solutions are designed to help customers enhance patient care, automate workflow, lower costs, improve productivity and provide better service to physicians.
How They Trade: EMAG has a 52 week high of $10.25 and a 52 week low of $1.87. Volume averages approximately 70K shares a day.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register and automatically be entered to win a Free Blackberry Pearl visit http://www.smallcapreview.com/subscribe.htm
editor@smallcapreview.com
www.smallcapreview.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
BTRX
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
